ITGAX and periodontal disorder: Furthermore, in periodontal disease, liraglutide was also found to downregulate M1-associated surface markers and cytokines, such as CD11c (Itgax), thereby reducing the proportion of M1 macrophages in gingival tissues and alleviating alveolar bone loss.